Leading experts in gastrointestinal oncology have long maintained that pancreatic cancer’s dismal prognosis stems not from inherent treatment resistance but from catastrophically late detection a position now backed by decades of survival data. This assertion drives the urgent need for molecular diagnostic tools capable of identifying malignancy before it becomes surgically unresectable. This research evaluated the diagnostic performance of multiple molecular biomarker approaches serum CA 19-9, circulating tumor DNA panels, microRNA signatures, and a novel multi-marker composite algorithm for early-stage pancreatic ductal adenocarcinoma detection in an Austrian patient population. We conducted a prospective diagnostic accuracy investigation at two Austrian academic medical centers between August 2019 and February 2021, enrolling 312 participants including 178 with histologically confirmed pancreatic adenocarcinoma across all AJCC stages and 134 high-risk controls with chronic pancreatitis or pancreatic cystic lesions under surveillance. Blood specimens were analyzed using next-generation sequencing for KRAS and TP53 mutations in cell-free DNA, quantitative reverse transcription PCR for a validated panel of six microRNAs (miR-21, miR-155, miR-196a, miR-210, miR-223, miR-375), and standard immunoassays for CA 19-9 and carcinoembryonic antigen. The multi-marker composite integrating all molecular platforms achieved the highest overall diagnostic sensitivity at 82.6% with specificity of 88.4%, markedly outperforming CA 19-9 alone (sensitivity 58.7%, specificity 81.2%) across all cancer stages. For stage I disease specifically, the composite algorithm detected 62.8% of cases compared with only 28.4% for CA 19-9 a clinically meaningful improvement that could shift diagnosis from palliative to curative intent in a substantial number of patients. The miRNA panel showed particular strength in early-stage detection (sensitivity 53.2% for stage IA), while ctDNA excelled at identifying patients harboring aggressive molecular profiles. Correlation analysis revealed moderate to strong associations between genomic markers (KRAS mutation and ctDNA mutant allele fraction, r=0.68) and between miRNA cluster members (miR-21 and miR-196a, r=0.71), confirming that different biomarker classes capture complementary biological information. These results establish that integrated multi-marker molecular diagnostics meaningfully improve early pancreatic cancer detection compared with conventional single-biomarker testing, supporting implementation of stepwise screening algorithms in high-risk populations.